Financial releases

First-half 2021 results and business update

US & Canada licensing agreement with Eton Pharmaceuticals for Crossject’s ZENEO® Hydrocortisone

2020 Annual results and business update

Crossject benefits from The French National Recovery Plan, with a €1.5 million grant

Crossject successfully raises €12 million in funding

First-half 2020 results and business update

Annual report 2019

End of the conversion of convertible bonds issued in 2019

Result of votes at Combined General Meeting of 25 june 2020

General meeting of 25 june 2020 - Q&R